Jasmer, R M <br/><br/>
Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.  [electronic resource] 

 -  American journal of respiratory and critical care medicine  Nov 2000 
 - 1648-52 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1073-449X 
<br/><br/><label>Standard No.: </label>10.1164/ajrccm.162.5.2003028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antitubercular Agents--administration & dosage<br/>Cost-Benefit Analysis<br/>Drug Administration Schedule<br/>Drug Costs<br/>Drug Therapy, Combination<br/>Female<br/>Health Care Costs<br/>Humans<br/>Isoniazid--administration & dosage<br/>Life Expectancy<br/>Male<br/>Middle Aged<br/>Outcome Assessment, Health Care<br/>Patient Compliance<br/>Radiography<br/>Recurrence<br/>Rifampin--administration & dosage<br/>San Francisco<br/>Tuberculosis, Pulmonary--diagnostic imaging